Enterprise Value
4.763B
Cash
329.5M
Avg Qtr Burn
-64.75M
Short % of Float
8.44%
Insider Ownership
17.68%
Institutional Own.
85.42%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Resmetirom (MGL-3196) (THR-B Agonist) Details Non-alcoholic steatohepatitis , Liver disease | NDA Submission | |
Resmetirom (MGL-3196) (THR-B Agonist) Details Fatty liver disease, Liver disease | Phase 3 Update |